TMP-301
Cocaine Use Disorder (CUD)
Key Facts
About Tempero Bio
Tempero Bio is a private, clinical-stage biotech developing TMP-301, a negative allosteric modulator of the mGluR5 receptor, for multiple substance use disorders. The company, an Aditum Bio portfolio company, has secured substantial Series B financing ($70M) to advance its lead candidate into Phase 2 trials following FDA IND clearance. Operating in a high-need, underserved market with limited pharmacological options, Tempero aims to provide a new class of treatment for addiction, a leading cause of preventable death in the U.S.
View full company profileAbout Tempero Bio
Tempero Bio is a private, clinical-stage biotech developing TMP-301, a negative allosteric modulator of the mGluR5 receptor, for multiple substance use disorders. The company, an Aditum Bio portfolio company, has secured substantial Series B financing ($70M) to advance its lead candidate into Phase 2 trials following FDA IND clearance. Operating in a high-need, underserved market with limited pharmacological options, Tempero aims to provide a new class of treatment for addiction, a leading cause of preventable death in the U.S.
View full company profileAbout Tempero Bio
Tempero Bio is a private, clinical-stage biotech developing TMP-301, a negative allosteric modulator of the mGluR5 receptor, for multiple substance use disorders. The company, an Aditum Bio portfolio company, has secured substantial Series B financing ($70M) to advance its lead candidate into Phase 2 trials following FDA IND clearance. Operating in a high-need, underserved market with limited pharmacological options, Tempero aims to provide a new class of treatment for addiction, a leading cause of preventable death in the U.S.
View full company profileAbout Tempero Bio
Tempero Bio is a private, clinical-stage biotech developing TMP-301, a negative allosteric modulator of the mGluR5 receptor, for multiple substance use disorders. The company, an Aditum Bio portfolio company, has secured substantial Series B financing ($70M) to advance its lead candidate into Phase 2 trials following FDA IND clearance. Operating in a high-need, underserved market with limited pharmacological options, Tempero aims to provide a new class of treatment for addiction, a leading cause of preventable death in the U.S.
View full company profile